psalexa
logo

Bronchiectasis Therapeutics Pipeline Analysis 2017

Bronchiectasis Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: September 2017
Report Code: LS11178
Available Format:
Pages: 100

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Overview

Bronchiectasis is a chronic infection in airways, due to which, some parts of the lung become injured, damaged and widened, allowing infected mucus to build up in lung pockets. In bronchiectasis, the airways tubes of lungs gradually lose their ability to clear off mucus which makes the bacteria nurture in airways tubes of lungs. Bronchiectasis can lead to serious health problems, such as respiratory failure, atelectasis, and heart failure. The initial lung damage that leads to bronchiectasis often begins in childhood. The disease can be of two types includes congenital and acquired. The signs and symptoms of bronchiectasis are feeling of tiredness or difficulty to concentrating, difficulty in breathing, cough incontinence, anxiety, depression, coughing up blood, chest pain, and joint pain. The diagnosis of bronchiectasis includes chest X-ray, computerised tomography (CT) scan, blood tests, lung function tests such as bronchoscopy, genetic blood tests. Various drug designations by the USFDA are propelling the growth of the bronchiectasis pipeline. For instance, Lipoquin, a drug candidate of Aradigm Corporation got orphan drug designation for bronchiectasis the USFDA. In May 2014, the USFDA also designated Linhaliq as a Qualified Infectious Disease Product (QIDP). ALT-07 and ALT-09, a drug candidate of Alitair Pharmaceuticals, Inc. also got orphan drug designation for bronchiectasis in the U.S.

 

BRONCHIECTASIS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)

 BRONCHIECTASIS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT

Insmed Incorporated is in the process of developing Amikacin Liposome Inhalation Suspension (ALIS) and INS1007 for the treatment of bronchiectasis. Many companies are more focused on developing their drug candidates as small molecule with the inhalation route of administration in the bronchiectasis therapeutics pipeline.

Pipeline Analysis

As of November 2017, the bronchiectasis therapeutics pipeline comprises of approximately 13 drug candidates in different stages of development.

Competitive Landscape

Some of the other key players developing drugs for the treatment of bronchiectasis include Aradigm Corporation, Bayer AG, Zambon SpA and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry